Inhibition of metabolic enzymes, such as α-glucosidase (α-GLy), is one of the accepted approaches in the treatment of diabetes mellitus (DM), which is one of the most common chronic endocrine diseases, along with arterial hypertension and obesity [1]. The gene discussed is SHMT2; the disease is diabetes mellitus.